71486-22-1 Vinorelbine

Superiority:

Product Name: Vinorelbine
Synonyms: 3’,4’-didehydro-4’-deoxy-c’-norvincaleukoblastin;AspidosperMidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8;ANX-530, KW-2307, 5'-Noranhydrovinblastine;vinorelbine D-tartrate;CL069;Vinorelbine, 98%, from Catharanthus roseus (L.) G. Don;nor-5’-anhydrovinblastine;VINORELBINE
CAS: 71486-22-1
MF: C45H54N4O8
MW: 778.93
EINECS:
Product Categories: reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract;ZOMIG;Active Pharmaceutical Ingredients;Antineoplastic;chemical reagent;pharmaceutical intermediate;phytochemical
Mol File: 71486-22-1.mol

Vinorelbine Chemical Properties
alpha  D20 +52.4° (c = 0.3 in CHCl3)
density  1.36±0.1 g/cm3(Predicted)
pka 11.36±0.60(Predicted)
Safety Information
Hazardous Substances Data 71486-22-1(Hazardous Substances Data)
Toxicity LD50 in mice (mg/m2): 72 i.v.; 78 orally (Mathé, Reizenstein)
MSDS Information
Vinorelbine Usage And Synthesis
Description Vinorelbine is a semisynthetic vinca alkaloid differing from vinblastine in the catharantine moiety of the molecule. It is claimed to have a broad spectrum of action both in vifro and in vivo; clinically it has been found effective in the treatment of non-small cell lung cancer, advanced breast cancer, ovarian cancer and Hodgkins disease.
Originator CNRS (France)
Uses antimigraine, 5HT[1B/1D] agonist
Definition ChEBI: A vinca alkaloid with a norvinblastine skeleton.
Brand name Navelbine (Pierre).
Clinical Use Vinorelbine is particularly useful in the treatment of advanced non–small cell lung cancer and can be administered alone or in combination with cisplatin. It is thought to interfere with mitosis in dividing cells through a relatively specific action on mitotic microtubules.